#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts
The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed, showed that a targeted "pan-RAS" drug doubled the survival time for patients whose pancreatic cancer has returned or stopped ...
By Endpoints News
· Apr 17, 2026
· via Endpoints News
Image: Endpoints News
Tags
theweekformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekSTAT News ↗
“These sides aren't talking to each other. And there's a lot riding on it”: The hosts of “Why Should I Trust Y…
The WeekBriefing
KFF’s new weekly podcast debuts April 2026, diving into healthcare’s financial and policy mechanics, starting …
The WeekBriefing
Drug Channels’ April roundup highlights how vertical integration and copay maximizers are changing the economi…